Medical Information

Rivastigmine transdermal patch is a cholinesterase inhibitor mainly used to treat mild to moderate Alzheimer's disease and Parkinson's disease dementia. It improves medication convenience and reduces gastrointestinal adverse reactions through transdermal administration.

1. Function and efficacy

(1) Pharmacological mechanism: By reversibly inhibiting acetylcholinesterase and butyrylcholinesterase, the level of acetylcholine in the cerebral cortex is increased, and cognitive function is improved.

(2) Clinical effect: It can delay disease progression, improve memory, attention, language ability, and daily living ability.

(3) Formulation advantages: Transdermal patches provide stable blood drug concentration, reducing first pass effects and gastrointestinal irritation of oral administration.

2. Scope of treatment

(1) Core indication: Suitable for symptomatic treatment of mild to moderate Alzheimer's dementia.

(2) Extended indication: Approved for the treatment of mild to moderate dementia associated with Parkinson's disease.

(3) Target audience: Adult patients (over 18 years old), elderly people do not need to adjust dosage, but individualized evaluation is required.

3. Usage restrictions

(1) Contraindications: It is contraindicated for individuals who are allergic to the ingredients of Kabardine or patches, as well as for patients with severe liver dysfunction.

(2) Caution: Patients with a history of asthma/chronic obstructive pulmonary disease, arrhythmia, peptic ulcers, and epilepsy should use with caution.

(3) Special population: The safety during pregnancy has not been established, and medication or breastfeeding should be stopped during lactation.